TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05947617
Drug: VIX001
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study utilizes a dose-escalation design with three arms or cohorts to evaluate the safety, tolerability, preliminary efficacy, and dose effect of VIX001, an amniotic fluid product, in patients with Post-Acute COVID-19 Syndrome (PACS) associated with neurological symptoms of cognitive impairment.~In all arms, the intervention will be administered at baseline and participants will be assessed at specified timepoints for safety, cognitive impairment, pain, activity, and quality of life. The primary objective is to evaluate the safety of VIX001, while the secondary objectives include assessing its potential efficacy and patient-reported outcomes.
Study: NCT05659927
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous injection. Subjects with a dose of less than or equal to 2 ml were given one injection, and subjects with a dose of more than 2 ml were given two injections. A group 0.5 ml, B group 1 ml, C group 2 ml, D group 4 ml.
Study: NCT00449124
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections of 0.5 mL of normal saline solution (0.9% NaCl).
Study: NCT06553391
Drug: The tetralogy of medication regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the rewarming process, the study group received an injection of 0.15g amiodarone via the extracorporeal circulation oxygenator. After heart re-beating：~1. If the heart rate is ≥70 beats per minute without specific therapy and in sinus rhythm or atrioventricular junctional rhythm, no special treatment is required. If the heart rate \<70 beats/min, intravenous injection of isoproterenol 2 ug may be administered.~2. In cases where there is sinus rhythm or atrioventricular junctional rhythm with a heart rate \<70 beats/min and perfusion pressure \<60mmHg, intravenous injection of ephedrine 10 mg + aminophylline 0.15 g should be given.~3. For patients with atrioventricular junctional rhythm or sinus rhythm and a heart rate \<70 beats/min but perfusion pressure ≥60mmHg, intravenous injections of aminophylline (0.15g) and ephedrine (10 mg) .~4. In cases where there is atrial fibrillation (AF), and the heart rate is ≥70 beats/min without special treatment.
Study: NCT06555146
Drug: Placebo, Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 subcutaneous injection on baseline day
Study: NCT05532358
Drug: anle138b (TEV-56286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anle138b (TEV-56286) as perpetrator
Study: NCT05072938
Drug: Mucotra SR Tablet 150mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebamipide/Nizatidine Combination Therapy
Study: NCT06375824
Drug: Bufei Recipe placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo was prepared using 5% of the drug, with color, odor, taste, appearance, and weight similar to the experimental group drug, and packaging consistent with the experimental group drug.
Study: NCT05533164
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in 250ml NaCl 0.9% intravenously
Study: NCT05109611
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.
Study: NCT04234867
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily for 5 days
Study: NCT05474001
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10mg bubivacain intrathecal ( 2ml ) with 20microgram intrathecal fentanyl
Study: NCT05924594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomized phase.
Study: NCT06393413
Drug: Jiedu Yizhi Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation after 24 weeks of drug treatment
Study: NCT05813964
Drug: TDF/FTC 300mg/200mg fixed-dose combination tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Event-driven dosing regimen
Study: NCT05813964
Drug: TAF/FTC 25mg/200mg fixed-dose combination tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Event-driven dosing regimen.
Study: NCT04574869
Drug: RLS-0071 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose IV infusion of 10 mg/kg RLS-0071
Study: NCT05298163
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo capsule matching the active drug will be given per day for 6 months, starting at the day of the time when inclusion criteria have been met
Study: NCT05815862
Drug: AL2846 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL2846 is a multi-target tyrosine kinase inhibitor.
Study: NCT06000748
Drug: MAP-Target Algorithm
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a clinical treatment algorithm that will determine the escalation and deescalation of vasoconstrictor utilization based on a target MAP, either high (≥80 mmHg) in the treatment group and low (\< 80 mmHg) in the comparator group.
Study: NCT05314998
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1660mg/m2/day in two divided doses administered orally for 21 days followed by 7 days' rest (one cycle) for six cycles i.e. 24 weeks
Study: NCT05432284
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (ambient air)
Study: NCT05432284
Drug: Beta-Myrcene
Normalized name: myrcene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure beta-myrcene vapor
Study: NCT05539248
Drug: CAN106 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction and maintenance dosing for cohort 1:~12 mg/kg on Day 1, 16 mg/kg on Day 8, and 20 mg/kg on Day 15 and every 4 weeks thereafter;
Study: NCT05539248
Drug: CAN106 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction and maintenance dosing for cohort 2:~30 mg/kg on Day 1, and 40mg/kg on Day 8 and every 4 weeks thereafter；
Study: NCT05539248
Drug: CAN106 80 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction and maintenance dosing for cohort 3:~60 mg/kg on day 1, and 80 mg/kg on day 15 and every 8 weeks thereafter.
Study: NCT06556186
Drug: Bromocriptin 2.5mg, 2-3 times a day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptin 2.5mg, 2-3 times a day
Study: NCT05685342
Drug: Acetaminophen/Ibuprofen fixed-dose combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of Acetaminophen (1000 mg)/Ibuprofen (300 mg) fixed-dose combination (total 100 ml)
Study: NCT05053009
Drug: Brufen Retard
Normalized name: Brufen Retard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg tablet of Brufen Retard will be adminstered orally one hour before local anesthesia
Study: NCT04713371
Drug: Keytruda Injectable Product
Normalized name: Keytruda Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keytruda (pembrolizumab): PD-1 inhibitor antibody~Injectable 50mg/mL, only 2 mL injected.
Study: NCT04713371
Drug: Yervoy Injectable Product
Normalized name: Yervoy Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yervoy (ipilimumab): Anti-CTLA-4 antibody~Injectable 5mg/mL, only 2 mL injected.
Study: NCT05515042
Drug: Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer)
Approvals — FDA: no, EMA: no, PMDA: no
Description: As included in arm/group descriptions
Study: NCT04688268
Drug: deep neuromuscular blockade
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Train of Four=0/4, Post tetanic count 1-2
Study: NCT05005065
Drug: IN-C005 X mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT05005065
Drug: IN-A001 Y mg
Normalized name: Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT05005065
Drug: IN-C005 Y mg
Normalized name: Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT05712720
Drug: Experimental: Group 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: RZ402 50 mg oral tablet, once daily for 3 months
Study: NCT05712720
Drug: Experimental: Group 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: RZ402 200mg oral tablet, once daily for 3 months
Study: NCT05712720
Drug: Experimental: Group 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: RZ402 400mg oral tablet, once daily for 3 months
Study: NCT05915117
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in form of capsule will be orally administered in subjects with metabolic syndrome and obesity over 8 weeks.
Study: NCT04761562
Drug: Platelet- and extracellular vesicle-rich plasma
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVRP will initially be applied to the gelatine sponge without prior exogenous activation, which will first be inserted into the middle ear cavity to support the reconstructed tympanic membrane. The remainder of the PVRP will then be exogenously activated with calcium chloride. Gel rich with platelets and extracellular vesicles will be created and applied on top of the reconstructed tympanic membrane. Finally, the external auditory canal will be filled with pieces of gelatine sponge soaked with PVRP.
Study: NCT06258980
Drug: Proph7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic recombinant FVII for heavily menorrhagic adolescent Glanzmanns Thrombaesthenia females
Study: NCT05937919
Drug: Intravenous injection of 68Ga-PMD22
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68Ga-PMD22 were intravenous injected into the patients before PET/CT scans
Study: NCT04704739
Drug: GLPG1205 film-coated tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of GLPG1205
Study: NCT04704739
Drug: GLPG1205 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of GLPG1205 as solid formulation
Study: NCT06632106
Drug: Tyrosine kinase inhibitor (TKIs)
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TKIs including Lenvatinib, Sorafenib, Apatinib, Donafenib, Bevacizumab
Study: NCT04991662
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion of Norepinephrine adjusted according to body weight to obtain higher pH value of fetal umbilical artery blood.
Study: NCT06501586
Drug: SGB-3908
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGB-3908 for sc injection
Study: NCT05502211
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: induction of anaesthesia using fentanyl
Study: NCT04911894
Drug: IBI321
Approvals — FDA: no, EMA: no, PMDA: no
Description: Several dose levels will be evaluated for IBI321 administered as a single agent. IBI321 will be given via IV infusion on Day 1 of each cycle until disease progression or loss of clinical benefit.
Study: NCT06077019
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants inhale placebo daily
Study: NCT05857358
Drug: Injection of the autologous adipose-derived stromal vascular fraction (AD-SVF)
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous uncultured (AD-SVF) will be isolated by digestion and centrifugation of adipose tissue from lipoaspiration.~Then, AD-SVF will be injected in 6 sites :~* 2 for the accessory labial glands (0.5mL in the upper lip and 0.5mL in the lower lip)~* 2 for the sublingual glands (0.5mL for each gland)~* 2 for the inner face of cheeks (0.5mL for each side)~The volume of injection will be of 3 mL containing 30 millions of AD-SVF viable nucleated cells for the total safety dose.
Study: NCT05899140
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin will be administered at a dose of 450 mg TDS (oral) or 10 mg/kg/dose QID iv (maximum 600mg QID iv) for a maximum of 7 days
Study: NCT04766463
Drug: SHR8554 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR8554 Injection; high dose
Study: NCT04766463
Drug: SHR8554 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR8554 Injection; low dose
Study: NCT04766463
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline Solution
Study: NCT05338034
Drug: HPG1860
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage form for clinical research is a dry-filled capsule for oral administration manufactured as strengths of 3 mg, 5 mg, and 8 mg.
Study: NCT05338034
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT04830579
Drug: Etoricoxib film-coated tablet 120 mg
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 120 mg of etoricoxib.
Study: NCT04830579
Drug: Arcoxia® film-coated tablet 120 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arcoxia® is manufactured by Frosst Iberica SA, Spain. Each tablet contains 120 mg of etoricoxib.
Study: NCT06069336
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised 3% hypertonic saline (NEBU-dose hypertonic). Nebulisation will be performed by trained study nurses or by parents under the supervision of a nurse
Study: NCT06069336
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0,9% normal saline (NEBU-dose isotonic). Nebulisation will be performed by trained study nurses or by parents under the supervision of a nurse
Study: NCT06158048
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT06462183
Drug: RGT-61159
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral MYB inhibitor
Study: NCT05347199
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: two doses, orally
Study: NCT05154955
Drug: 10XB-101 Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: One of the three concentrations of 10XB-101 will be evaluated against placebo for submental fat reduction.
Study: NCT05154955
Drug: 10XB-101 Vehicle Solution for Injection
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is the placebo control
Study: NCT04258410
Drug: Placebo oral soft chew
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo identical to experimental drug contained in soft chew
Study: NCT05998525
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients who meet the inclusion criteria and after catheterization will be randomized to receive a placebo pill 24 hours and upon discharge treatment will continue for 12 months
Study: NCT04258826
Drug: LY3154207
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3154207 administered orally.
Study: NCT04258826
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally.
Study: NCT06129643
Drug: Conventional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional disinfection using 2.5% sodium hypochlorite and 17% EDTA
Study: NCT05792813
Drug: LGYY mimetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: LGYY = Linggui Yangyuan paste
Study: NCT05792813
Drug: WZYZ
Normalized name: I do not have enough information to determine the full generic name for the drug abbreviation 'WZYZ'. Drug abbreviations can vary and may not have a clear or standardized mapping to their full generic names. Without more context about the specific drug or clinical trial data, I cannot provide the full generic name. I apologize that I cannot give you a more definitive answer.
Approvals — FDA: no, EMA: no, PMDA: no
Description: WZYZ= Wuzi Yanzong oral solution
Study: NCT05792813
Drug: WZYZ mimetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: WZYZ= Wuzi Yanzong oral solution
Study: NCT04979988
Drug: Lortlatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: as provided in real world practice
Study: NCT03534102
Drug: Improved Opioid-Tapering Instructions
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied to first and second experimental groups in the form of discharge instructions and directions from nursing staff.
Study: NCT05850091
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmacotherapy for reduction in LDL cholesterol level
Study: NCT05850091
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule with sugar pill that mimics active study drugs
Study: NCT05819541
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral or parenteral corticosteroid (e.g., dexamethasone, methylprednisolone)
Study: NCT05328414
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intranasal fast dissolving film to be applied intranasal. it contains 0.005 mg Presdnisolone
Study: NCT05604885
Drug: AP1189, 60 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP1189 tablets for oral use
Study: NCT05604885
Drug: AP1189, 80 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP1189 tablets for oral use
Study: NCT05604885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets for oral use
Study: NCT05288855
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo capsule
Study: NCT04771481
Drug: Normal Saline 10 mL Injection
Normalized name: normal saline 10 mL Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 10 ml intravenous slowly push in 5min before endoscopy 30-120 min
Study: NCT05451199
Drug: ICP-488
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICP-488 will be administered as tablet
Study: NCT05451199
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered as tablet
Study: NCT05262270
Drug: Placebo (PLB) Injectable matched to XR-BUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of subcutaneous injections (Week 0, 4)
Study: NCT06421688
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After participants underwent induction of anesthesia, Ascorbic acid (Vitamin C Injection) was administered at a dosage of 50 mg/kg, diluted to 50 ml using saline, with a total amount not exceeding 4 g; pumping was performed using a micro pump at a rate of 25 ml/h.
Study: NCT05171673
Drug: Licart™ (diclofenac epolamine) topical system
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Licart™ (diclofenac epolamine) topical system was designed to deliver the nonsteroidal anti-inflammatory drug (NSAID) diclofenac to the site of a minor soft tissue injury through topical application. This investigational product (IP) is a 10 cm x 14 cm topical system comprised of an adhesive material containing 1.3% diclofenac epolamine that is bound to a non-woven polyester felt backing and covered with a polypropylene film release liner. The release liner is removed prior to topical application to the skin.
Study: NCT05218733
Drug: General anesthesia using intravenous fentanyl (1µgm/kg)
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive general anesthesia using intravenous fentanyl (1µgm/kg)
Study: NCT06618118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Use
Study: NCT05739929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets twice daily
Study: NCT06627335
Drug: TCS
Normalized name: TCS-OX2-29
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid
Study: NCT04862741
Drug: NX-13 250mg IR
Normalized name: Replesta NX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
Study: NCT04862741
Drug: NX-13 500mg MR
Normalized name: Replesta NX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
Study: NCT06102525
Drug: RZ-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant adenovirus harboring the modified ribozyme construct with HSV-tk as a therapeutic transgene
Study: NCT05292638
Drug: CKDB-501A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection CKDB-501A
Study: NCT05292638
Drug: Botox®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection Botox®
Study: NCT06727435
Drug: non-sedation strategy
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients eligible for this study will undergo non-sedation strategy, which continuous analgesia without sedation is performed with remifentanil. The remifentanil will be titrated (from 0.1µg/kg/min to 0.2ug/kg/min) every 10-15 minutes to achieve the goal for sedation (RASS score maintaining -2 to + 1). The patients in the non-sedation trial do not receive any sedatives but could receive bolus doses (2.5 or 5mg) of morphine for analgesia.
Study: NCT05981534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be used for 6 months
Study: NCT05598151
Drug: HM97662
Approvals — FDA: no, EMA: no, PMDA: no
Description: To evaluate the safety, tolerability, preliminary anti-tumor efficacy, PK and PD of HM97662 in solid tumors
Study: NCT05586230
Drug: Optimized background regimen (OBR) for multidrug-resistant TB (MDR-TB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-study prescribed OBR will vary according to local, national and/or international guidelines for treatment of children with MDR-TB. Administered in addition to single dose of Pa.
Study: NCT05387837
Drug: D-4517.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor)